LEXINGTON, Mass., Apr 01, 2010 (BUSINESS WIRE) –AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) will host a conference call
and webcast today at 8:00 am ET to discuss today’s announcement that
AMAG Pharmaceuticals, Inc. and Takeda Pharmaceuticals Company have
entered into a strategic collaboration agreement related to Feraheme(R)
(ferumoxytol) Injection for intravenous (IV) use in all therapeutic
indications in select ex-US territories.
AMAG Conference Call and Webcast Access
To access the conference call via telephone, please dial (877) 412-6083
from the United States or (702) 495-1202 for international access. A
telephone replay will be available from approximately 11:00 a.m. ET on
April 1, 2010 through midnight April 2, 2010. To access a replay of the
conference call, dial (800) 642-1687 from the United States or (706)
645-9291 for international access. The passcode for the live call and
the replay is 64493010.
The call will be webcast and accessible through the Investors section of
the Company’s website at www.amagpharma.com.
The webcast replay will be available from approximately 11:00 a.m. ET on
April 1, 2010 through midnight April 15, 2010.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes
its proprietary technology for the development and commercialization of
a therapeutic iron compound to treat iron deficiency anemia and novel
imaging agents to aid in the diagnosis of cancer and cardiovascular
disease. On June 30, 2009, AMAG received approval from the U.S. Food and
Drug Administration to market Feraheme(R) (ferumoxytol) Injection for
intravenous (IV) use for the treatment of iron deficiency anemia in
adult chronic kidney disease patients. For additional company and
product information, please visit www.amagpharma.com.
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
SOURCE: AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals
Amy Sullivan, +1-617-498-3303
or
Carol Miceli, +1-617-498-3361
